Month: October 2016

The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease

BÜHLMANN Quantum Blue® fCAL Citation: Abej, E. et al. The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory BowelDisease Can J Gastroenterol Hepatol. 2016;2016:2483261. Epub 2016 Sep 28.DOI:10.1155/2016/2483261.  PMID: 27774443.  This Canadian study represents how FCAL testing is utilized in the field for monitoring disease activity in IBD.  The reference for the cut-off
Continue Reading

Entretien Avec Yvonne Schallberger, Bioanalytica Lucerne

fCAL® turbo de BÜHLMANN Santé Canada Licence: 96808 English Version Entretien Avec Yvonne Schallberger, Bioanalytica Lucerne Madame Schallberger, vous avez dernièrement choisi d’utiliser le nouveau test fCAL® turbo de BÜHLMANN. Ce test s’adapte parfaitement sur des équipements de chimie clinique et permet l’analyse la calprotectine dans les selles en environ 10 minutes. Pourriez-vous nous indiquer les
Continue Reading

Evaluation of the BÜHLMANN fCAL® turbo Test at Bioanalytica Lucerne

BÜHLMANN fCAL® turbo is for Research Use Only in the US. Not to be used in diagnostic procedures. Health Canada License: 96808 French Version Interview with Yvonne Schallberger, Bioanalytica Lucerne Mrs. Schallberger, you recently decided to introduce the new calprotectin assay, BÜHLMANN fCAL® turbo, which offers a calprotectin result in random access mode on all USUAL
Continue Reading

BUHLMANN Highlights – ACE Kinetic Enzymatic Assay

BÜHLMANN ACE Kinetic Enzymatic Assay Simple, Fast, Versatile Automated Assay for use on Multiple Clinical Chemistry Platforms ACE kinetic is FDA 510(k) cleared. For in vitro Diagnostic Use. BÜHLMANN's Clinical Chemistry product line is a unique selection of high quality assays for routine and specialized testing in clinical chemistry.  Employing the long lasting experience with ACE activity on
Continue Reading

BUHLMANN Flow CAST Kinase Inhibition Assay and Utilization in Research

BÜHLMANN's Kinase Inhibition Assay has been utilized in several publications in various fields of study such as drug discovery, cancer research, autoimmune disease research, and more. Several key kinases that are molecular targets in drug discovery, such as PI3Kγ and PI3Kδ, SYK, BTK are main components in the basophil activation signaling pathways. Our Assay  has been
Continue Reading

Discovery of PI3K Delta Inhibitors for the Treatment of Inflammatory and Autoimmune Disease

Flow CAST® – Kinase Inhibition Assay Citation: Matthews, D.J. et al. Discovery of PI3K delta inhibitors for the treatment of inflammatory and autoimmune disease. 2012 New York Academy of Sciences Meeting Poster.  "Importantly, PWT143 inhibits basophil activation (as measured by surface CD63 expression in a whole blood assay) with subnanomolar potency in response to anti-IgE stimulation
Continue Reading

TGR-1202 Suppresses Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Cells via Selective Inhibition of PI3Kδ Kinase

Flow CAST® – Kinase Inhibition Assay Citation: VakkalankaS. et al. TGR-1202 suppresses acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) cells via selective inhibition of PI3Kδ kinase. 2012 ASH Meeting Poster. "TGR-1202 demonstrated significant potency against PI3Kδ (22.2 nM) with several fold selectivity over the α (>10000), β (>50), and γ (>48) isoforms. Additionally, the
Continue Reading

Brutontyrosine Kinase Inhibitor Ibrutinib(PCI-32765) has Significant Activity in Patients with Relapsed/Refractory B-cell Malignancies

Flow CAST® – Kinase Inhibition Assay Citation: Advani, R.H. et al. Brutontyrosine kinase inhibitor ibrutinib(PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J ClinOncol. 2013 Jan 1; 31(1): 88-94. PMID: 23045577 "A decrease in anti–IgE-stimulated basophil degranulation was observed, consistent with the role of BTK downstream of the high-affinity IgE receptor."
Continue Reading

PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models

Flow CAST® – Kinase Inhibtion Assay Citation: Winkler, DG et al. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74. doi: 10.1016/j.chembiol.2013.09.017. Epub 2013 Nov 7. PMID: 24211136. "These studies demonstrate that IPI-145 exerts profound effects on adaptive and innate immunity by inhibiting
Continue Reading

Proactive Therapeutic Drug Monitoring of Infliximab: A Comparative Study of a New Point-of-Care Quantitative Test with Two Established ELISA Assays

BÜHLMANN Quantum Blue® Infliximab Trough Level Assay Citation: Afonso J, Lopes S et al. Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays. Aliment Pharmacol Ther. 2016 Oct;44(7):684-92. doi: 10.1111/apt.13757. Epub 2016 Aug 10. PMID: 27507790 First Publication using our Quantum Blue® Infliximab Trough Level Assay We are very
Continue Reading
Sign Up for BUHLMANN Updates!

Enter your email and stay on top of things,